In the STEP clinical trials, semaglutide 2.4 mg (Wegovy) demonstrated average weight loss of approximately 15% of initial body weight over 68 weeks when combined with lifestyle interventions
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomized clinical trials
[24] Finally, a 2020 Cochrane systematic review found insufficient evidence to suggest that metformin monotherapy reduced all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or end-stage renal disease when compared to DPP-4 inhibitors for the treatment of type 2 diabetes
Uses licensed US clinicians

Both medications can increase heart rate and blood pressure, creating additive cardiovascular strain The appetite-suppressing effects of both drugs may lead to excessive weight loss or nutritional deficiencies No direct pharmacokinetic interaction exists, but pharmacodynamic effects overlap significantly Regular monitoring of blood pressure, heart rate, and weight is essential when using both medications Always disclose all medications to your healthcare provider before starting either treatment Medication Interaction Risk Checker Answer these questions to understand your personal risk profile when considering both medications: Table of Contents Understanding How Wegovy and Adderall Work Differently Cardiovascular Concerns When Combining These Medications Overlapping Appetite Suppression Effects and Nutritional Risks Monitoring Requirements for Safe Concurrent Use Who Should Avoid This Combination Entirely Practical Guidance for Managing Both Medications Wegovy vs Adderall Comparison Table Key Takeaways When to Seek Professional Advice Frequently Asked Questions Understanding How Wegovy and Adderall Work Differently To properly understand the safety considerations of taking these medications together, it helps to first grasp how each one works in your body
